The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44941-44954

  Altuntas, Sara ^a   Rossin, Federica ^a   Marsella, Claudia ^a   D'Eletto, Manuela ^a   Hidalgo, Laura Diaz ^a   Farrace, Maria Grazia ^a   Campanella, Michelangelo ^a,b   Antonioli, Manuela ^a   Fimia, Gian Maria ^c,d   Piacentini, Mauro ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF SALENTO   (Italy)

Author keywords

Autophagy; Beclin1; LC3; Pyruvate kinase M2; Transglutaminase type 2

Indexed keywords

BECLIN 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M2; REGULATOR PROTEIN; ULK1 PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; CARRIER PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN SERINE THREONINE KINASE; SERINE THREONINE PROTEIN KINASE ULK1; SIGNAL PEPTIDE; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TYROSINE; ULK1 PROTEIN, HUMAN;

AMIDATION; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CONTROLLED STUDY; DOWN REGULATION; GLYCOLYSIS; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ENZYMOLOGY; FIBROSARCOMA; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; AUTOPHAGY-RELATED PROTEIN-1 HOMOLOG; BECLIN-1; CARRIER PROTEINS; CELL LINE, TUMOR; FIBROSARCOMA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEIN INTERACTION MAPS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID HORMONES; TRANSFECTION; TRANSGLUTAMINASES; TYROSINE;

EID: 84953426327     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6759     Document Type: Article

References (62)

1. Wang Z, Griffin M. TG2, a novel extracellular protein with multiple functions. Amino Acids. 2011; 42:939-949.
2. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002; 27:534-9.
3. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991; 5:3071-7.
4. Malorni W, Farrace MG, Rodolfo C, Piacentini M. Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection. Curr Pharm Des. 2008; 14:278-88.
5. Park D, Choi SS, Ha K-S. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids. 2010; 39:619-31.
6. Zemskov EA, Janiak A, Hang J, Waghray A, Belkin AM. The role of tissue transglutaminase in cell-matrix interactions. Front Biosci. 2006; 11:1057-76.
7. Kiraly R, Demeny M, Fesus L. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J. 2011; 278:4717-39.
8. Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007; 5: e327.
9. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science. 1994; 264:1593-6.
10. Mishra S, Murphy LJ. Tissue transglutaminase has intrinsic kinase activity. Identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem. 2004; 279:23863-8.
11. Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, Kikuchi M, Sato Y, Saito Y. A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J. 2003; 373:793-803.
12. Altuntas S, D'Eletto M, Rossin F, Hidalgo LD, Farrace MG, Falasca L, Piredda L, Cocco S, Mastroberardino PG, Piacentini M. Type 2 Transglutaminase, mitochondria and Huntington's disease: Menage a trois. Mitochondrion. 2014; 19:97-104.
13. Mastroberardino PG, Farrace MG, Viti I, Pavone F, Fimia GM, Melino G, Rodolfo C, Piacentini M. "Tissue" transglutaminase contributes to the formation of disulphide bridges in proteins of mitochondrial respiratory complexes. Biochim Biophys Acta. 2006; 1757:1357-65.
14. Malorni W, Farrace MG, Matarrese P, Tinaria, Ciarlo L, Mousavi-Shafaei P, D'Eletto M, Di Giacomo G, Melino G, Palmieri L. The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrial-dependent apoptosis. Cell Death Differ. 2009; 16:1480-92.
15. Brand MD, Pakay JL, Ocloo A, Kokoszka J, Wallace DC, Brookes PS, Cornwall EJ. The basal proton conductance of mitochondria depends on adenine nucleotide translocase content. Biochem J. 2005; 392:353-62.
16. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther. 2007; 115:232-45.
17. Piacentini M, D'Eletto M, Falasca L, Farrace MG, Rodolfo C. Transglutaminase 2 at the crossroads between cell death and survival. Adv Enzymol Relat Areas Mol Biol. 2011; 78:197-246.
18. Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2 and its substrates in human diseases. Front Biosci. 2006; 11:1758-73.
19. Wang Z, Perez M, Caja S, Melino G, Johnson TS, Lindfors K, Griffin M. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell Death Dis. 2013; 4:1-13.
20. Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition. Oncotarget. 2015; 6:20525-39. Doi:10.18632/oncotarget.3890.
21. Fimia GM, Kroemer G, Piacentini M. Molecular mechanisms of selective autophagy. Cell Death Differ. 2013; 20:1-2.
22. Nikoletopoulou V, Papandreou ME, Tavernarakis N. Autophagy in the physiology and pathology of the central nervous system. Cell Death Differ. 2015; 22:398-407.
23. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011; 147:728-41.
24. Nardacci R, Amendola A, Ciccosanti F, Corazzari M, Esposito V, Vlassi C, Taibi C, Fimia GM, Del Nonno F, Ippolito G, D'Offizi G, Piacentini M. Autophagy plays an important role in the containment of HIV-1 in nonprogressor-infected patients. Autophagy. 2014; 10:1167-78.
25. Kaur J, Debnath J. Autophagy at the crossroads of catabolism and anabolism. Nat Rev Mol Cell Biol. 2015; 16:461-72.
26. Gabandé-Rodríguez E, Boya P, Labrador V, Dotti CG, Ledesma MD. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. Cell Death Differ. 2014; 6:864-75.
27. Colasanti T, Vomero M, Alessandri C, Barbati C, Maselli A, Camperio C, Conti F, Tinari A, Carlo-Stella C, Tuosto L, Benincasa D, Valesini G, Malorni W, Pierdominici M, Ortona E. Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes. Cell Death Dis. 2014; May 29; 5:e1265. doi:10.1038/cddis.2014.211. PMID:24874737
28. Rossin F, D'Eletto M, Macdonald D, Farrace MG, Piacentini M. TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy. Amino Acids. 2012; 42:1793-802.
29. D'Eletto M, Farrace MG, Falasca L, Reali V, Oliverio S, Melino G, Griffin M, Fimia GM, Piacentini M. Transglutaminase 2 is involved in autophagosome maturation. Autophagy. 2009; 5:1145-54.
30. Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res. 2007; 5:241-9.
31. Strnad P, Zatloukal K, Stumptner C, Kulaksiz H, Denk H. Mallory-Denk-bodies: lessons from keratincontaining hepatic inclusion bodies. Biochim Biophys Acta. 2008; 1782:764-774.
32. Rossin F, D'Eletto M, Falasca L, Sepe S, Cocco S, Fimia GM, Campanella M, Mastroberardino PG, Farrace MG, Piacentini M. Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis. Cell Death Differ. 2014; 22:1-11.
33. Garcia-Heredia JM, Carnero A. Decoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chain. Oncotarget. 2015; 6:41582-99; Doi:10.18632/oncotarget.6057.
34. Wakabayashi T, Craessaerts K, Bammens L, Bentahir M, Borgions F, Herdewijn P, Staes A, Timmerman E, Vandekerckhove J, Rubinstein E, Boucheix C, Gevaert K, De Strooper B. Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat Cell Biol. 2009; 11:1340-6.
35. Qiu XB, Shao YM, Miao S, Wang L. The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci. 2006; 63:2560-70.
36. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 2012; 22:407-17.
37. Mazurek S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011; 43:969-80.
38. Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ. 2013; 20:21-30.
39. Bandyopadhyay U, Sridhar S, Kaushik S, Kiffin R, Cuervo AM. Identification of regulators of chaperone-mediated autophagy. Mol Cell. 2010; 39:535-47.
40. Wang DW, Peng ZJ, Ren GF, Wang GX. The different roles of selective autophagic protein degradation in mammalian cells. Oncotarget. 2015; 6:37098-116. doi:10.18632/oncotarget.5776.
41. Peng X, Gong F, Chen Y, Jiang Y, Liu J, Yu M, Zhang S, Wang M, Xiao G, Liao H. Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-α-mediated signaling. Cell Death Dis. 2014; 5: e1367.
42. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011; 145:732-44.
43. Luo W, Semenza. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2011; 2:551-6. Doi:10.18632/oncotarget.299.
44. Mizushima N, Yoshimori T, Levine B. Methods in Mammalian Autophagy Research. Cell. 2010; 140:313-26.
45. Bjørkøy G, Lamark T, Pankiv S, Øvervatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009; 452:181-97.
46. Trocoli A, Bensadoun P, Richard E, Labrunie G, Merhi F, Schläfli AM, Brigger D, Souquere S, Pierron G, Pasquet JM, Soubeyran P, Reiffers J, Ségal-Bendirdjian E, Tschan MP, Djavaheri-Mergny M. p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. Cell Death Differ. 2014; 21:1852-61.
47. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007; 282:24131-45.
48. Song Y, Kirkpatrick LL, Schilling AB, Helseth DL, Chabot N, Keillor JW, Johnson GVW, Brady ST. Transglutaminase and Polyamination of Tubulin: Posttranslational Modification for Stabilizing Axonal Microtubules. Neuron. 2013; 78:109-23.
49. Esposito C, Caputo I. Mammalian transglutaminases: Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J. 2005; 272:615-31.
50. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452:230-3.
51. Orrù S, Caputo I, D'Amato A, Ruoppololl M, Esposito C. Proteomics identification of acyl-acceptor and acyl-donor substrates for transglutaminase in a human intestinal epithelial cell line. Implications for celiac disease. J Biol Chem. 2003; 278:31766-73.
52. Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GVW, Mehta K. Transglutaminase regulation of cell function. Physiol Rev. 2014; 94:383-417.
53. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010; 40:280-93.
54. White E. The role for autophagy in cancer. J Clin Invest. 2015; 125:42-6.
55. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012; 45:598-609.
56. Gong J, Muñoz AR, Chan D, Ghosh R, Kumar AP. STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget. 2014; 5:2529-41. Doi:10.18632/oncotarget.1810.
57. You L, Wang Z, Li H, Shou J, Jing Z, Xie J, Sui X, Pan H, Han W. The role of STAT3 in autophagy. Autophagy. 2015; 11:729-39.
58. Vessoni AT, Filippi-Chiela EC, Menck CF, Lenz G. Autophagy and genomic integrity. Cell Death Differ. 2013; 20:1444-54.
59. Gonzalez Y, Aryal B, Chehab L, Rao VA. Atg7-and Keap1-dependent autophagy protects breast cancer cell lines against mitoquinone-induced oxidative stress. Oncotarget. 2014; 6:1526-37. Doi:10.18632/oncotarget.1715.
60. Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, Mariño G, Kepp O, Michaud M, Perfettini JL, Kroemer G, Deutsch E. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ. 2014; 1:92-9.
61. Hasima N, Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis. 2014; Nov 6;5:e1509. doi:10.1038/cddis.2014.467. PMID:25375374
62. Wang Z, Shi X, Li Y, Fan J, Zeng X, Xian Z, Wang Z, Sun Y, Wang S, Song P, Zhao S, Hu H, Ju D. Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis. 2014; Dec 11;5:e1563. doi:10.1038/cddis.2014.503. PMID:25501824.